MultiCell Technologies, Inc. (MCET)

Market Cap	5.00K
Revenue (ttm)	805.24K
Net Income (ttm)	-253.61K
Shares Out	5.00B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,001
Average Volume	100,468
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	-50.55
RSI	47.91
Earnings Date	n/a

About Accolade

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a d...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1962
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: MCET

Financial Performance

In 2014, MultiCell Technologies's revenue was $49,318, a change of 0.00% compared to the previous year's $49,318. Losses were -$380,071, -69.22% less than in 2013.